Interestingly, research has emphasized that CPT2 is significantly overexpressed and pro-carcinogenic in epithelial ovarian cancer, whereas it is underexpressed and shows reduced long-term survival in another type of ovarian cancer, primary ovarian plasmacytoid carcinoma, whereas low levels of CPT2 promote apoptosis through the NADPH/ROS/NFκB signaling pathway [11,126]. Here, CPT2 is linked to ovarian carcinoma.